AlphaTON Capital Stock Falls 13% On Preclinical Cancer Data Update

(RTTNews) - AlphaTON Capital Corp. (ATON) shares dropped 12.40 percent to $4.02 on Friday following the release of new preclinical results at the Society for Immunotherapy of Cancer Annual Meeting by the company and Cyncado Therapeutics, its oncology subsidiary.

ATON is trading at $4.02, down from a previous close of $4.59 on the Nasdaq. The stock started the day at $3.71 and has since jumped between $3.62 and $4.21. The trading volume went above its average of 0.82 million, reaching 1.74 million.

The 52-week trading range for the shares is $2.95 to $15.8180.

The study showed potent antitumor activity in a variety of mouse models, pointing out the possible synergy between selective A2B and A2A antagonists and cancer vaccines.